摘要
目的探讨西肽普兰治疗肿瘤患者伴发焦虑抑郁情绪的临床疗效及安全性。方法将100例肿瘤伴发焦虑抑郁情绪患者随机分为两组，每组50例，两组患者均接受常规抗肿瘤治疗，研究组在此基础上联合西肽普兰治疗，观察4周。于治疗前及治疗4周未采用焦虑自评量表、抑郁自评量表评定焦虑抑郁情绪，副反应量表评定不良反应。结果治疗4周末研究组焦虑情绪改善率为72．34％，抑郁情绪改善率为76．60％，对照组分别为8．70％，4．35％，研究组显著高于对照组（P〈0．01）；研究组焦虑自评量表、抑郁自评量表评分均较对照组下降显著（P〈0．01）；两组不良反应无差异性。结论西肽普兰治疗肿瘤患者伴发的焦虑抑郁情绪效果显著，安全性高，可显著提高患者的生活质量，促进肿瘤的帮体治疗。
Objective To explore the clinical efficacy and safety of citalopram in treatment of tumor patients with anxiety-depression emotions. Methods 100 patients were randomly divided into two groups of 50 ones each,to both groups given routine antineoplaston,and research group were plus citalopram for 4 weeks.Anxiety-depression emotions were assessed with the Self-rating Anxiety Scale（SAS） and Self-rating Depressin Scale（SDS） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） before treatment and at the end of the 4th week. Results Improvement rates of anxiety and depression emotion were respectively 72.34% and 76.60% in the research and 8. 70% and 4. 35% in the control group at the end of the 4th week, the former were significantly higher than the latter（P〈0.01） ;Scores of both the SAS and SDS lowered more significantly in the research than in the control group（P〈0.01）. Adverse reactions of the two groups were not different. Conclusion Citalopram has a notable effect and high safety in the treatment of tumor patients with anxiety-depression emotions,can improve patients ＇ quality of life significantly and promote neoplastic holistic therapy.
出处
《临床心身疾病杂志》
CAS
2010年第1期11-12,共2页
Journal of Clinical Psychosomatic Diseases
